UBS analyst Danielle Antalffy lowered the firm’s price target on Baxter (BAX) to $21 from $24 and keeps a Neutral rating on the shares. Baxter delivered a Q3 sales miss vs. consensus across all businesses excluding Advanced Surgery and also cut its quarterly dividend, the analyst tells investors in a research note. Consensus numbers for 2026 will likely have to come down, and sales growth in 2026 might be tough to come by, the firm says.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAX: